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Macrophages are abundant in the lower respiratory tract. They play a central role in the innate response to
infection but may also modulate excessive inflammation. Both macrophages and ciliated epithelial cells
respond to infection by releasing soluble mediators, leading to the recruitment of innate and adaptive effector
cells. To study the role of lung macrophages in acute respiratory viral infection, we depleted them by the
inhalation of clodronate liposomes in an established mouse model of respiratory syncytial virus (RSV) disease.
Infection caused an immediate local release of inflammatory cytokines and chemokines, peaking on day 1,
which was virtually abolished by clodronate liposome treatment. Macrophage depletion inhibited the activation
(days 1 to 2) and recruitment (day 4) of natural killer (NK) cells and enhanced peak viral load in the lung (day
4). However, macrophage depletion did not affect the recruitment of activated CD4 or CD8 T cells, weight loss,
or virus-induced changes in lung function. Therefore, lung macrophages play a central role in the early
responses to viral infection but have remarkably little effect on the adaptive response occurring at the time of
peak disease severity.
Macrophages are key effector cells of the innate immune
response to pathogen invasion but are also thought to have an
immune-suppressive effect in the lung, limiting excess inflam-
mation (12). Normal resting alveolar macrophages (AM) pro-
duce low levels of inflammatory cytokines and are less actively
phagocytic than their counterparts in other tissues, possibly
due to lower levels of the phagocytic receptor CD11b (12). AM
activation causes increased phagocytosis and production of
numerous proinflammatory cytokines, including tumor necro-
sis factor alpha (TNF-), interleukin-6 (IL-6), and IL-8 (2).
They are critical in determining the outcome of a number of
respiratory infections, playing a role in controlling the replica-
tion and spread of both viruses, e.g., influenza virus (36), and
bacteria, e.g., Mycobacterium tuberculosis (21, 22).
Respiratory syncytial virus (RSV) is a nonsegmented, nega-
tive-strand RNA virus of the family Paramyxoviridae. It is the
leading cause of infant hospital admissions, causing 70% of
bronchiolitis hospitalizations in the developed world (10). The
relative contribution of the adaptive and innate responses to
the pathogenesis of RSV disease is unclear. The importance of
T cells in RSV disease has been extensively studied in the
mouse model, where skewed Th1/Th2 responses are associated
with different forms of lung disease (30). In humans, severe
infantile bronchiolitis is associated with markers of Th2 immu-
nity (1, 23), and RSV-specific T cells producing gamma inter-
feron (IFN-), IL-4, and IL-5 have been detected in children
with RSV, with IL-4 and IL-5 being detected only in those
children with severe bronchiolitis (31, 20). In the 1960s, the
vaccination of children with formalin-inactivated RSV caused
exacerbated illness when the children subsequently became
infected with RSV (18, 24). A recent study of fatal cases of
RSV bronchiolitis in infants has shown that death is associated
with a lack of evidence of adaptive immune responses to in-
fection, such as an absence of recruitment of cytotoxic T cells
and lymphocyte-derived cytokines, robust viral replication, and
increased apoptosis within bronchiolar epithelial cells (39). In
addition, single-nucleotide polymorphism screening of infants
hospitalized for severe RSV bronchiolitis shows that polymor-
phisms in genes associated with innate immunity, such as
IFNA2 and NOS2, as well as the known polymorphisms in the
adaptive pathways have strong associations with RSV disease
in childhood (17).
Liposome-encapsulated dichloro-methylene-diphosphonate
(clodronate) is taken up by phagocytic cells in vitro and in vivo.
The liposome bilayers are disrupted in the lysosome by phos-
pholipases, allowing the escape of clodronate into the cell;
once the clodronate has accumulated sufficiently, the macro-
phage is irreversibly damaged and dies by apoptosis (38). In
mice, the administration of clodronate liposomes (CL) can
therefore be used to selectively deplete macrophages (37). The
depletion of macrophages from the lungs is associated with an
increased pulmonary immune response characterized by den-
dritic cell (DC) trafficking (16, 35). Macrophage depletion of
mice followed by RSV infection has been shown to result in
increased viral titers (3); however, the role that macrophages
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play in initiating and modulating the immune responses and
disease after RSV infection has not been fully elucidated.
To delineate the role of macrophages in the immune re-
sponse to RSV infection, we depleted macrophages by the
intranasal administration of CL prior to infection and charac-
terized both the innate and adaptive immune responses and
their effects on viral replication and disease. While macro-
phage depletion strongly inhibited the immediate release of
inflammatory mediators and the activation and recruitment of
natural killer (NK) cells after viral infection, it had little effect
on the adaptive response or overt disease.
MATERIALS AND METHODS
Mice and virus stocks. Eight-week-old female BALB/c mice (Harlan Ltd.,
United Kingdom) were maintained under pathogen-free conditions in accor-
dance with institutional and United Kingdom Home Office guidelines. In order
FIG. 1. Immune response to RSV titration in a BALB/c mouse model. Mice were infected i.n. with 100 l containing 5  105, 2  105, or 1  105
PFU of RSV or PBS (control). Illness was assessed by weight loss (a) and whole-body plethysmography (b). Viral titer was measured in the lung
on day 4 by infectious-focus assay (c). On day 7, APC (CD11c MHC-II) numbers (d) and CD4 (e) and CD8 (f) T-cell numbers plus their
activation states (g and h) were analyzed. Bars/data points represent the means  SEM of the results from four animals and are representative
of two separate experiments. ***, P  0.001; **, P  0.01; *, P  0.05, for test versus control values (a and b), and where indicated by solid
horizontal lines (c, e, f, g, and h), determined by ANOVA.
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to obtain a pathogenic stock of RSV, human RSV (type A2 strain from the
ATCC) was plaque purified and grown in HEp-2 cell culture in RPMI 1640
medium supplemented with 2% fetal bovine serum, 2 mM L-glutamine, 100-U/ml
penicillin, and 100-g/ml streptomycin.
Mouse treatment and infection. For macrophage depletion, mice were
treated intranasally (i.n.) with 100 l of CL suspension (a gift from Nico van
Rooijen, Boehringer GmbH, Germany), or with the control, while under light
anesthesia with isoflurane. Mice were infected i.n. with 100 l of the chosen
dose of RSV strain A2 while under light anesthesia with isoflurane. The
weight and baseline lung function (assessed by noninvasive, barometric,
whole-body plethysmography [Buxco, United Kingdom] as described in ref-
erence 8) of mice were monitored daily until they were sacrificed by pento-
barbitone injection. Bronchoalveolar lavage (BAL) was performed by inflat-
ing the lungs via the trachea with 1 ml of 12 mM lidocaine in Eagle’s
minimum essential medium. The BAL cells were prepared for flow cytometry,
and the BAL cell-free supernatant was retained for enzyme-linked immu-
nosorbent assay (ELISA). Collagenase-digested lung tissue was prepared for
flow cytometry analysis, and the supernatant from a homogenized lung was
used in an RSV infectious-focus assay to measure the viral load. The super-
natants from the lung tissue, strained through 100-m filters, were tested by
ELISA.
Flow cytometric analysis. The following antibodies were used: Pacific Blue–
anti-CD11c (eBioscience, United Kingdom), Pacific Blue–anti-CD4, fluores-
cein isothiocyanate conjugated with anti-major histocompatibility complex
class II antigen (FITC–anti-MHC-II), FITC–anti-CD44, FITC–anti-CD69,
phycoerythrin (PE)–anti-CD86, PE–anti-CD80, PE–anti-DX5, PE–anti-tu-
mor necrosis factor (TNF), antigen-presenting cell (APC)–anti-F4/80, APC–
anti-CD8, PE–Cy7–anti-CD11b, PE–Cy7–anti-CD3, and PE–anti-RSV M2
pentamer (Proimmune, United Kingdom), plus isotype controls (antibodies
from BD Biosciences, United Kingdom, unless otherwise stated). Cells were
blocked with Fc block (anti-CD16/32; BD), and surface staining was carried
out on live cells resuspended in phosphate-buffered saline (PBS)–1% bovine
serum albumin–0.1% azide–5 M EDTA (fluorescence-activated cell sorter
buffer). For intracellular TNF analysis, cells were cultured for 4 h with
GolgiStop (BD). Cells were run on a cyan ADP LX 9 color flow cytometer
(Dako, United Kingdom) with data analyzed using the Dako Summit analysis
program.
Cytokine and chemokine analysis. Cytokines and chemokines were quanti-
fied by ELISA performed according to the manufacturers’ instructions. TNF
was assessed using a Biosource Cytoset kit (Biosource, United Kingdom),
IFN- was assessed with capture antibody (Hycult Biotechnology, United
Kingdom) and a two-step detection (rabbit anti-IFN- from PBL Biomedical
Laboratories, United Kingdom, and mouse anti-rabbit serum from Jackson
ImmunoResearch, United Kingdom), and IFN-, IL-6, IL-12 (p70), IL-15,
CCL3 (MIP-1), CCL5 (RANTES), and keratinocyte chemokine were as-
sessed using RD Systems Duoset antibody pairs (RD Systems, United
Kingdom). Briefly, Immunosorb ELISA plates (Nunc, United Kingdom) were
coated with capture antibody and blocked either with 1% bovine serum
albumin in PBS or, in the case of IFN-, with 2.5% fetal calf serum in PBS
with 0.02% NaN3. Sample or standard was added, and bound cytokines were
detected by biotinylated anticytokine antibody, avidin horseradish peroxi-
dase, and tetramethylbenzidine. Color development was blocked with 2 M
H2SO4, and optical densities were read at 450 nm. The concentration of
cytokines in each sample was determined from the standard curve.
Infectious-focus assay. RSV titer was assessed in lung homogenate by titration
on HEp-2 cell monolayers in 96-well, flat-bottom plates. Twenty-four hours after
infection, monolayers were washed, fixed with methanol, and incubated with
peroxidase-conjugated goat anti-RSV antibody (Biogenesis, United Kingdom).
Infected cells were detected using 3-amino-9-ethylcarbazole and infectious units
enumerated by light microscopy.
Statistical analysis. Statistical analysis was performed using a two-way analysis
of variance (ANOVA) statistic program with GraphPad Prism. Significance was
noted when P was 0.05.
FIG. 2. Macrophage depletion by CL treatment. Mice were given i.n. 100 l of liposomes, containing undiluted clodronate (100% CL), 30%
CL in PBS, or undiluted empty liposomes (PL). AM in BAL cells (a), macrophages (M) in lung cells (b), total BAL cells (c), and total lung cells
(d) were counted on days 1 and 3 posttreatment. Values from naı¨ve animals are displayed as broken lines on each plot. Bars represent means 
SEM of the results from five animals, and data are representative of three separate experiments. *, P  0.05, where indicated by solid horizontal
lines (determined by ANOVA); ns, not significant.
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RESULTS
Titration of infectious RSV dose. RSV was titrated in naı¨ve
8-week-old BALB/c mice at doses of 5  105, 2  105, and 1 
105 PFU per mouse. Doses of 5  105 or 2  105 PFU per
mouse resulted in significant weight loss on day 7 postinfection
compared to that of the naı¨ve animals (Fig. 1a) and increased
the baseline enhanced pause (Penh), representing increased
respiratory effort, on days 5 to 8 (Fig. 1b). The peak viral titer
measured on day 4 by an infectious-focus assay confirmed that
the RSV load in the lung was proportional to the dose admin-
istered (Fig. 1c). The dose-dependent recruitment of CD11c
MHC-II APC and CD8 T cells (CD3 CD8) was also evi-
dent on day 7 postinfection, while the peak recruitment of CD4
T cells (CD3 CD4) correlates with the highest viral dose
(Fig. 1d to f). The activation of T cells was also related to the
dose of RSV administered, with the expression of the early
activation marker CD69 being greatest for mice which received
5  105 PFU and lowest for those which received 1  105 PFU
of RSV (Fig. 1g and h).
Intranasal administration of CL. In order to determine the
correct concentration needed to deplete local macrophages
without initiating excess inflammation, we titrated the stock
concentration of CL. Naı¨ve 8-week-old BALB/c mice were
given i.n. 100% or 30% CL, diluted in PBS to a total volume of
100 l. Control mice received either PBS or empty liposomes
(PL). Flow cytometric analysis of the BAL cells for CD11c
AM with a low level of MHC-II (MHC-IIlo) (19) showed that
both the 100% and 30% CL treatments resulted in an 	80%
reduction in the AM number on days 1 and 3 after treatment
(Fig. 2a). Macrophage depletion in the remaining lung tissue
was less marked, with a 50% reduction after either dose (Fig.
2b). Interestingly, treatment with empty liposomes caused a
significant increase in the number of recovered macrophages
on day 1 postdepletion compared to the number in PBS-
treated animals, probably due to macrophage activation caused
by the phagocytosis of liposomes.
Total BAL and lung cell numbers were increased after treat-
ment with 100% CL but not with 30% CL (Fig. 2c and d);
hematoxylin and eosin staining revealed that the additional
cells were polymorphonuclear in appearance (data not shown).
No treatment resulted in weight loss or altered lung function as
measured by baseline Penh (data not shown). The dose of 30%
CL was chosen, as this gave the maximal depletion of macro-
phages and minimal inflammation.
CL treatment depletes macrophages during infection. On
day 0 of infection (day 3 after CL treatment), there was a
marked depletion of CD11c MHC-IIlo cells. CD11c MHC-
IIlo AM constituted approximately 80% of the BAL cells of
healthy mice on day 1 postinfection compared to 20% of the
BAL cells of mice which received CL (Fig. 3a). At the same
time point in the lungs, macrophages represented 4% of the
total cell population after CL treatment compared to 7% with-
out this treatment (Fig. 3b). RSV infection caused the percent-
age of AM in the BAL cells to drop to a level similar to that of
the CL group by day 8 postinfection. The percentage of lung
macrophages also dropped as the disease progressed.
The AM of naı¨ve mice are typically CD11c CD11blo,
while the DC of naı¨ve mice are CD11c CD11b (16). The
BAL cells of a naı¨ve BALB/c mouse are entirely CD11c
MHC-IIlo CD11b
. CL treatment preferentially depleted
CD11b
 AM (Fig. 3c), and the remaining CD11c MHC-
IIlo cells were predominantly CD11b, suggestive of imma-
ture DC. CL treatment led to an early increase in CD11c
cells with a high level of MHC-II (MHC-IIhi) cells compared
FIG. 3. Clodronate treatment during RSV infection depletes macrophages. Mice were treated with 30% CL 3 days prior to i.n. infection with
2  105 PFU of RSV. Using fluorescence-activated cell sorter analysis, macrophages were defined as CD11c MHC-IIlo and DC were defined as
CD11c MHC-IIhi. The percentages of BAL cells (a) and lung macrophages (M) (b and c) and the percentages of DC (d and e) were plotted.
Data points represent means  SEM of the results from five animals, and data are representative of three separate experiments. ***, P  0.001;
**, P  0.01; *, P  0.05, for test versus control values determined by ANOVA.
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to that of the untreated mice on day 0; however, the expan-
sion of MHC-IIhi APC in the lungs on day 8 postinfection
was actually reduced by macrophage depletion (Fig. 3d).
The majority of these APC were CD11b (Fig. 3e), suggest-
ing that they were DC.
Mediator release by macrophages. Macrophages are widely
thought to be a significant source of TNF, which is readily
available for release following infection. Intracellular staining
for TNF in lung macrophages and DC showed that prior to
RSV infection, 60% of the macrophages, but only 20% of the
DC, stained positive for TNF (Fig. 4a and b). After day 2 of the
RSV infection, there was a rapid drop in the number of TNF
macrophages; CL treatment appeared to selectively deplete
TNF macrophages but had no effect on TNF DC.
On day 1 after RSV infection, there was a peak of inflam-
matory mediators in the airways, including TNF, IL-6, CCL3,
IFN-, CCL5, and IFN-. All were significantly reduced by the
CL treatment of mice prior to RSV infection, with the excep-
tion of IFN- (Fig. 4c to h). RSV infection resulted in a less
pronounced peak of chemokine and cytokine release in the
surrounding lung tissue; however, macrophage depletion did
not affect the concentrations detected (data not shown).
Effects of macrophage depletion on viral load and subse-
quent disease. Despite the elimination of early inflammatory
signals after macrophage depletion, weight loss was not af-
fected (Fig. 5a); neither were increases in the baseline Penh
upon infection (Fig. 5b). There was, however, a significant
increase in RSV viral titer in the lungs on day 4 postinfection
in mice that were pretreated with CL (means  standard
errors of the means [SEM] of 1,044  497.2 PFU/lung for
PBS/RSV versus 5,028  1,575 PFU/lung for CL/RSV; P 
0.05), but levels of viral clearance were similar (Fig. 5c).
Immune responses to infection. Macrophage depletion dur-
ing RSV infection did not cause significant changes in the total
cell recruitment to the lungs compared to that in the nondepleted
mice (Fig. 6a). Furthermore, the proportion of CD4 and CD8
T-cell recruitment was unaffected (Fig. 6b and c), and their acti-
vation, as measured by CD69 expression, was also unaltered (Fig.
6d and e). The majority of the RSV-specific CD8 T cells in the
BALB/c mice respond to a peptide within the RSV M2 protein.
Use of an M2-specific pentamer to stain for RSV-specific CD8 T
cells revealed no changes following CL treatment, with 	24% of
the CD8 T cells being RSV M2 positive on day 8 irrespective of
treatment (Fig. 6f). Additionally, the humoral immune response
FIG. 4. Macrophage depletion reduces early cytokine and chemo-
kine production. Mice were treated with 30% CL 3 days prior to i.n.
infection with 2  105 PFU of RSV. Intracellular TNF in lung mac-
rophages (M) (a) and DC (b) was measured by flow cytometry. TNF
(c), IL-6 (d), CCL3 (e), IFN- (f), CCL5 (g), and IFN- (h) levels in
BAL cells were measured by ELISA. Data points represent means 
SEM of the results from five animals; data are representative of three
separate experiments. ***, P  0.001; **, P  0.01; *, P  0.05, for
test versus control values determined by ANOVA.
FIG. 5. Macrophage depletion during RSV infection does not affect weight loss but increases viral load. Mice were treated with 30% CL 3 days prior
to i.n. infection with 2 105 PFU of RSV. Weight (a) and body plethysmography (b) were recorded throughout. (c) Viral titer was measured on harvested
lung tissue supernatants by infectious-focus assay. Data points represent means SEM of the results from five animals; data are representative of three
separate experiments. ***, P  0.001; **, P  0.01; *, P  0.05, for test versus control values determined by ANOVA.
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was unaffected by depletion. There was no change in the serum
levels of RSV-specific immunoglobulin on either day 8 or day 16
postinfection (Fig. 6g).
During RSV infection, in the presence of macrophages, NK
cells (CD3
 DX5) were recruited to the lungs and their
numbers peaked on day 4. Interestingly, CL treatment pre-
vented this NK cell recruitment (Fig. 6 h). Further, CD69, an
activation marker, was rapidly upregulated on the surfaces of
NK cells after RSV infection, peaking on day 1. The depletion
of macrophages also reduced CD69 expression (Fig. 6i).
DISCUSSION
Depleting macrophages by the inhalation of CL caused a
profound inhibition of the early release of inflammatory cyto-
kines into the airways after RSV infection and lessened the
activation and recruitment of NK cells. Despite the virtual
abolition of early inflammatory mediator release and a rise in
viral load at day 4, there was no change in the weight loss, lung
function deterioration, or T-cell recruitment that characterizes
the later stages of RSV infection. In view of the known viral
sensing, proinflammatory, and immunomodulatory effects of
AM, depletion seemed to have remarkably little effect on these
responses.
A number of studies have observed a very early release of
cytokines and chemokines after RSV infection similar to that
seen here (6). Our data suggest that this release is AM depen-
dent. This is supported by other studies that show that the
activation of NF-B signaling pathways, which are key in ini-
tiating many proinflammatory responses, in the lungs of mice
infected with RSV was entirely dependent on the presence of
AM (7).
In contrast with our findings that the marked reduction of
proinflammatory mediators in the airways did not affect the
overall disease, the targeted removal of individual mediators
does lead to reduced disease. CCL3
/
 mice have reduced
RSV inflammation (6), the use of depleting antibody to re-
move TNF reduces weight loss associated with RSV infection
(15), and neutralizing the function of CCL5 by the administra-
FIG. 6. Macrophage depletion reduces NK cell recruitment and activation but does not alter the adaptive immune responses. Mice were treated
with 30% CL 3 days prior to i.n. infection with 2  105 PFU of RSV. Total lung cell counts (a) and percentages of CD4 (b), CD8 (c), activated
CD4 (d), activated CD8 (e), and RSV-specific CD8 T cells (f) in the lungs of CL- or PBS-treated mice at different time points after RSV infection
are shown. (g) Anti-RSV serum antibody was detected by RSV-specific immunoglobulin ELISA, and values from 1/400 serum dilutions are shown.
NK cell number (h) and activation (i) in lung postinfection are shown. Data points/bars represent means  SEM of the results from five animals,
and data are representative of three separate experiments. ***, P  0.001; **, P  0.01; *, P  0.05, for test versus control values determined
by ANOVA; ns, not significant; Ig, immunoglobulin; OD, optical density.
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tion of Met-RANTES (a competitive inhibitor) reduces both
the CD4 and CD8 responses to RSV (4). In addition, non-
IFN-responsive, STAT-1 knockout mice show increased illness
and Th2-skewed disease (5). These studies describe the effects
of systemic and presumably complete removal of either the
factor or the signaling, whereas we specifically depleted AM
and found altered cytokine levels in the BAL cells but not the
lungs. This reflects a greater (80%) reduction in the number of
AM in the BAL cells than the 50% reduction in the number of
macrophages in the lung tissue. Therefore, it is possible that
the inflammatory mediators in the surrounding lung tissue and
alternative sites, such as the lymph nodes and spleen, contrib-
ute to the disease seen in the current study.
DC are thought to “license” NK cells, potentiating their
activation and cytotoxicity (25, 26). Here we show in naı¨ve
lungs, where DC are scarce, that AM are required to both
recruit and activate NK cells in response to RSV infection.
Recently, human macrophages have been shown to be able to
activate NK cells by a mechanism that involves contact-medi-
ated signaling through the immune synapse (28). The loss of
this signaling may explain the loss of NK cell activation that we
observed. It has been shown that IFN- production by resident
cells in the liver promotes MIP-1 production and subsequent
NK cell migration (32, 33). Therefore, it seems likely that the
loss of chemokine production, such as with MIP-1, may also
be critical in determining NK cell recruitment to the lungs.
We have previously shown that NK cells are a major source
of early IFN- during viral infection (13). In addition, they play
an essential role in RSV immunity along with specific T cells,
as the depletion of both NK cells and CD8 T cells led to the
dissemination of virus from the lungs to the lymph nodes (14).
This suggests that the loss of early (days 1 to 4) IFN- seen
after depletion is most likely due to reduced NK cell recruit-
ment; furthermore, the loss of NK cells may also explain the
increased viral titer on day 4. AM could also potentially be
directly antiviral; they are the first cells to encounter pathogens
in the airways, acquiring the vast majority of inhaled particles
by efficient phagocytosis (16). Although viral titers in the lung
on days 1 and 2 were unaffected by macrophage depletion,
suggesting that initial RSV replication takes place mainly in
epithelial cells, at the peak of replication on day 4, depletion
led to a higher viral load. This points to a role for AM in
controlling antiviral activity against RSV infection. Virus was
cleared by day 8 in both normal and macrophage-depleted
mice; later clearance of virus is associated with effective CD8
and antibody responses, both of which were unaffected by CL
treatment.
In addition to their direct cytotoxic role, NK cells also have
been shown to strongly influence the subsequent CD8 T-cell
response via their cytokine secretion (13). Although IFN- and
NK cells were reduced up to day 4 in our study, subsequent
T-cell numbers were not altered with the CL treatment. In
addition to the normal T-cell response to RSV, weight loss and
lung function were unaffected by AM depletion. T-cell infiltra-
tion correlated well with these indicators of disease after RSV
infection (Fig. 1), and exacerbated CD8 T-cell responses have
been strongly associated with both measures of disease, in both
RSV (9) and influenza A virus (27) infection.
The dual role of macrophages in both regulation and inflam-
mation may explain why, despite decreasing inflammatory me-
diator release, AM depletion has no effect on the adaptive
immune response to infection and therefore disease. AM sup-
press the migration (16) and antigen presentation capacity (11)
of DC. AM removal has been shown to increase the trafficking
of antigen toward the lymph nodes (16); this may be the case
in RSV infection. Such increased antigen transport may be due
to the presence of enhanced DC numbers in the lungs during
the early stages of infection in macrophage-depleted mice. Our
results support those of Wijburg et al., showing that DC are the
main APC for the induction of virus-specific T-cell responses,
since these responses were still effectively induced in the ab-
sence of AM (40). The increased viral burden, and antigen
load, on day 4 postinfection may also promote enhanced T-cell
recruitment, compensating for the loss of inflammatory signals.
NK cells may also play a role in the suppression of T-cell
responses (29, 34), and therefore, the decrease in NK cell
recruitment following AM depletion may allow an increase in
the T-cell response.
In conclusion, the depletion of lung macrophages dampens
the innate response to RSV infection and increases the peak
viral load but does not change weight loss or lung function, as
parameters of disease. Therefore, our findings support a role
for T-cell-mediated factors in RSV disease. However, in in-
fants with diminished adaptive responses to viral infection,
macrophages and the innate responses that they control could
be critical in controlling viral load in the lung.
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